1. Introduction {#sec1}
===============

Underdeveloped mandibles can cause severe psychological and functional impact upon the growing child and may be associated with life-threatening complications such as obstructive sleep apnea (OSA) due to severe airway constriction \[[@B1], [@B2]\]. The prevalence of OSA in children is approximately 3% \[[@B4]\]. Patients with OSA usually have underdeveloped mandible (mandible) \[[@B5], [@B6]\]. The mortality rate due to OSA has been reported to reach 15% of the affected individuals \[[@B7], [@B8]\]. This increased mortality is mainly attributed to the retruded position of the mandible which compromises the airway \[[@B9]\].

When the airway is compromised because of severe mandible underdevelopment, jaw-positioning appliances \[[@B10]\], nasopharyngeal airway \[[@B11]\], orthodontic plates with velar extension \[[@B12]\], intubation \[[@B13]\], tongue-lip adhesion \[[@B14]\], continuous positive airway pressure (CPAP) \[[@B15]\], tracheostomy \[[@B16]\], mandibular advancement with orthognathic surgery/distraction osteogenesis \[[@B17], [@B18]\], or an anterior mandibular positioning device is used to manage the airway obstruction \[[@B19], [@B20]\].

It is to be noted that tracheotomy and mandibular distraction osteogenesis (DO) have major limitations; they are lifesaving and provide substantial lengthening of the mandible quickly. In spite of recent advancements, the tracheostomy procedure remains a treatment with serious and frequent side effects. These side effects include potential tissue traumatization, injury of the laryngeal or tracheal mucosa, and/or other complications (e.g., pneumothorax, hemorrhage, wound complication, tracheal stenosis, and laryngeal stenosis) \[[@B16]\]. To avoid tracheostomies, distraction osteogenesis of the mandible (surgical lengthening of the mandible) has recently been recommended as a viable option for pediatric patients with upper airway obstruction due to mandibular deficiency \[[@B17]\]. This technique has been described as an alternative to tracheostomy in neonates (6 to 26 days of age) to improve airway and breathing \[[@B18]\].

Conversely, improving the airway in OSA adult patients with the use of a removable mandibular advancement device (MAD) has recently been shown to have a success rate of only 54.8% \[[@B19]\]. Advancing the mandible with oral appliances depends solely on patient\'s compliance and has been reported to be effective in short term only \[[@B20]\]. Nonetheless, the long-term efficacy of all above-mentioned treatment modalities is unknown.

2. Mandibular Growth {#sec2}
====================

The condylar cartilage in the mandible is a secondary cartilage. It has been shown that mechanical stimuli are necessary for the normal growth of this type of cartilage \[[@B21]--[@B25]\]. Bite-jumping appliances (orthodontic/orthopedic functional appliances) have long been used for "growth modification" of the mandible in the field of orthodontics and craniofacial orthopedics. However, the effectiveness of these appliances has been criticized and is still considered an area of controversy \[[@B26]\]. Other currently available mechanical loading techniques, for example, electroforce 3200 mechanical testing machine, are not clinically applicable for severe mandibular underdevelopment due to the large size of the device (mechanical testing machine) or because patients can not fit within the proposed devices (electroforce or mechanical testing machines) \[[@B21]\].

3. Current Treatment Modalities and Challenges {#sec3}
==============================================

3.1. Bite-Jumping Appliances (Functional Appliances) {#sec3.1}
----------------------------------------------------

Growth modification of the mandible using functional appliances (FAs) has been used to enhance forward positioning of the mandible. They are commonly used clinically to enhance mandibular growth in patients with underdeveloped mandibles. Recent animal experiments have demonstrated significant increase in the endochondral ossification (bone formation within the growing cartilage) at the mandibular condyle in response to the mandibular protrusive forces \[[@B21], [@B28], [@B29]\]. This forward mandibular positioning has been hypothesized to solicit a sequence of cellular events that lead to increased vascularization, new bone formation, and enhanced condylar growth \[[@B30]\]. Also, a recent clinical trial on the effectiveness of twin block functional appliance on mandibular growth in 15 boys and 19 girls ranging in age from 9 years 3 months to 10 years 8 months at the start of treatment showed that its use increases the mandibular length 2.3 mm more than that of a control group \[[@B31]\]. Controversially, other clinical trials of FAs therapy have demonstrated either no substantial growth enhancement or increased mandibular growth only at the initial stage, with the growth phenotype of the mandible returning to its original pattern afterwards \[[@B32], [@B33]\]. Interestingly, FAs were reported to increase the number of replicating mesenchymal stem cells in growing rats at both the mandibular condyle and the glenoid fossa \[[@B34]\]. In a related study, a correlation was demonstrated between the application of FAs as a mechanical stimulator and the number of stem cells in mandibular condyles and the glenoid fossa \[[@B35]\]. These studies demonstrated that the number of mesenchymal cells in a given locus normally determines the potential for bone growth in that area and that the number of mesenchymal cells in the glenoid fossa is directly correlated with the amount of bone produced during natural growth and mandibular advancement \[[@B34], [@B35]\]. It has been hypothesized that a lack of native stem cells in the mandibular condyle and glenoid fossa contributes to the underdevelopment of the mandible \[[@B34], [@B35]\]. Consequently, development of new techniques to foster stem cell recruitment to the growing condyles and the glenoid fossa becomes practical.

Although the exact mechanism of FAs involvement in promoting mandibular growth is not fully understood, previous reports have shown that FAs enhance mandibular growth through an increase in the production of Runx2 \[[@B29]\], which is a transcription factor that belongs to the Runt domain gene family. The Runx2 promotes osteoblast\'s differentiation and function by transcriptionally upregulating all the major osteoblast-specific genes, including osteocalcin, type-I collagen, bone sialoprotein, osteopontin, alkaline phosphatase, and collagenase-3 \[[@B36]\]. Also, FAs enhance Sox9 and type II collagen expression in rats \[[@B37]\], a result that has been confirmed by immunostaining techniques \[[@B21], [@B28]--[@B30]\].

3.2. Low-Intensity Pulsed Ultrasound {#sec3.2}
------------------------------------

Low-intensity pulsed ultrasound (LIPUS) produces mechanical waves that propagate through biological tissues at a pulse frequency of 1.5 MHz with a pulse repetition frequency of 1 kHz. At an output power of 30 mW/cm^2^, LIPUS can stimulate tissue growth without heating \[[@B16], [@B17]\]. A daily treatment with LIPUS for 20 minutes has been established as a favorable treatment modality in the field of orthopedics \[[@B38]--[@B41]\]. This treatment protocol has been found to stimulate bone healing after fracture in a variety of human and animal models by promoting new vascularization and bone formation \[[@B37]--[@B39]\]. Also, this technique has been applied successfully to promote growth and healing after distraction (i.e., excessive separation of bony segments) of the tibia in a rabbit model and after distraction of the callus \[[@B38], [@B41]\]. Daily direct application of LIPUS for 4 weeks also stimulated mandibular bone growth in rats and rabbits \[[@B23], [@B24]\]. However, achieving similar results in monkeys required four months of treatment \[[@B42]\] and about a year in humans (when combined with FAs) \[[@B43]\] ([Figure 1](#fig1){ref-type="fig"}). Such long periods of daily application of LIPUS are challenging and highly demanding for a clinical implementation. Thus, the development of an approach to boost the stimulatory effect of LIPUS on bone growth is necessary.

Recent reports have shown that LIPUS has anabolic effect in chondrocytes with increased stimulation when LIPUS is applied for longer durations \[[@B44]\]. Furthermore, the current consensus in the literature is that the stimulatory effect of therapeutic ultrasound on bone formation is dose dependent (daily treatment time) \[[@B44]--[@B46]\]. Angiogenesis has also been shown to be increased with LIPUS treatment, thus improving the blood flow to the treatment area that is critical for bone growth \[[@B47], [@B48]\]. In addition, it has been shown that LIPUS promotes stem cell expansion and differentiation \[[@B49]--[@B51]\]. Indeed, the application of ultrasound in stem cell expansion and differentiation as well as in bone mineralization and regeneration has gained considerable attention in recent years \[[@B52], [@B53]\].

The mechanism of mandibular growth enhancement by LIPUS is not fully understood. The hypothesized mechanism of action of LIPUS to stimulate mandibular growth is through increase in vascular endothelial growth factor (VEGF) and Runx2 in bone healing since these have been shown to be correlated to increased mandibular growth \[[@B48]\]. LIPUS is known to increase the expression of VEGF and Runx2 in bone healing \[[@B47]\]. Also, LIPUS has been shown to increase the expression of osteocalcin, Runx2, and bone sialoprotein in stem cells \[[@B54]\]. In addition, the expression of Runx2, Msx2, Dlx5, osterix, bone sialoprotein, and bone morphogenetic protein-2 has been shown to be enhanced in MG-63 osteoblasts \[[@B55]\]. Sox9 is known to be a crucial molecule in stem cell proliferation, condensation, and chondrocyte differentiation \[[@B56]--[@B58]\]. Runx2 is involved in chondrocyte differentiation, whereas VEGF and collagen type X are involved in endochondral ossification \[[@B48], [@B56]\]. Integrins may act as mechanotransducers that can transform acoustic pulsed energy into intracellular biochemical signals that subsequently induce cell proliferation \[[@B59]\]. Although the mechanisms are still to be uncovered, current knowledge indicates that FAs and LIPUS have a potential synergistic effect in enhancing mandibular growth through mutual upregulation of Sox9, Runx2, and type-II collagen. This synergistic effect may be further increased by neovascularization produced by local application of bone marrow stem cells to mandibular condyles \[[@B60]--[@B66]\]. A critical need still exists for an optimized and effective technique to promote mandibular growth in a reasonable period of time (2-3 months in humans) for clinical application. Yet, it is to be tested the effect of LIPUS on increase of Sox9, Runx2, VEGF, and Type-II collagen in mandibular condyles treated by LIPUS. It is possible that once LIPUS parameters are optimize (Frequency, intensity, and treatment time), they may be used clinically with minimum compliance of growing children with underdeveloped mandibles.

Growth hormone: growth hormone (GH) is an anterior pituitary hormone that induces general growth including bone \[[@B67]--[@B71]\]. It has been reported that systemic administration of GH enhances bone formation in animals \[[@B70]\]. Also, GH plays an important role not only in skeletal growth and development in young people but also in regulating bone remodeling throughout life \[[@B72]\]. Cell surface receptors for GH have been reported to be present in the temporomandibular joint (TMJ) \[[@B73]\].

Children undergoing GH therapy for short stature or isolated GH deficiency (who usually have normal jaw size) can experience a burst in jaw growth while on the GH therapy \[[@B74], [@B75]\].

In spite of the potential side effects of GH administration such as inducing body weight gain \[[@B76]\] and upregulation of proto-oncogenes like C-jun in liver \[[@B77]\], kidney, and other vital tissues \[[@B78]\], there has been an attempt to enhance mandibular growth by local injection of recombinant growth hormone (rGH) into the posterior attachment of mandibular condyle of growing rats with or without LIPUS application \[[@B79]\]. The hypothesized mechanism of action of local rGH application is to increase endochondoral bone formation in the mandibular condyles without possible side effect of systemic use of rGH. The findings indicated that local rGH injection into mandibular condyles in rats increased mandibular growth compared to the control group. The study concluded that the used rGH dose does not have synergistic effect in combination with LIPUS application in enhancing mandibular bone volume or mandibular surface area while the combined treatment increased mandibular head length compared to either treatment alone (Figures [2(a)](#fig2){ref-type="fig"} and [2(b)](#fig2){ref-type="fig"}). Also, local injection of rGH increased C-jun in the liver \[[@B79]\]. Therefore, it seems to be prudent to have an optimized rGH/LIPUS protocol to enhance mandibular growth with minimum potential side effects and to study the effect of rGH in the long term. Future studies are needed to test the hypothesis that local injection of different rGH doses to mandibular condyle can modulate molecular mechanisms of mandibular growth, especially Runx2, VEGF, Sox9, and type-II collagen. Until the optimized rGH dose with or without LIPUS application can stimulate mandibular growth with minimum or no systemic side effect, the possible clinical application of rGH may not be foreseen.

3.3. Photobiomodulation {#sec3.3}
-----------------------

Photobiomodulation has been recently reported to be an effective therapeutic technique by which low-level laser light is used to enhance tissue growth and regeneration. This technique has been shown to minimize pain after orthodontic appliance adjustment \[[@B80]--[@B82]\] and minimize inflammation caused by the orthodontic appliances \[[@B83]\]. Low-level laser (LLL) therapy is a form of photobiomodulation that has been shown to enhance bone formation in the midpalatal suture after orthodontic maxillary expansion \[[@B84]\]. Also, the use of LLL has been proposed to accelerate tooth movement by inducing alveolar bone remodeling in the form of bone formation and cell proliferation in the tension side as well as increase the number of osteoclasts in the compression side of the orthodontically moved teeth \[[@B85], [@B86]\].

Light emitting diode (LED) is a monochromatic red-to-near infrared (NIR) light that has been shown to enhance retinal function in an animal model when used in the range of 630--1000 nm \[[@B87]\]. The wavelength of LED is close to that used in LLL (600--1000 nm) with similar energy \[[@B87]\]. Both the LED and the LLL result in photobiomodulation effects \[[@B88]--[@B90]\]. However, the difference between LED and the LLL is that LLL is a LASER with the characteristic of coherency, whereas LED light is not coherent, and therefore it is not expected to result in any side effects \[[@B88]--[@B91]\]. The LED can also be produced at a lower cost compared to the LLL and it can be safely applied to a larger area of the body surface. It has been shown that LED light can alter the cellular metabolism following absorption by a cellular photoacceptor known as cytochrome c-oxidase \[[@B87], [@B91]\]. Moreover, it has been hypothesized that LED-mediated photobiomodulation may have potential in stimulating mandibular growth. A pilot study on the effect of LLL and LED on mandibular growth stimulation reported that both LED and LLL can stimulate mandibular growth in growing rats \[[@B92]\]. The objective of this pilot study was to compare the possible effect of LLL and LED of similar wavelength (850 nm) and energy output (6 J/cm^2^) with or without the use of functional appliance (FA) on mandibular condylar growth in growing rats. The experimental design of this pilot study was as follows. Twenty-four growing Sprague-Dawley rats (6 weeks old) were divided into six groups of four animals each. Group 1 received LLL, group 2 received LLL + FA, group 3 received LED, group 4 received LED + FA, group 5 received FA and was used as a positive control group, and group 6 received no treatment and was used as negative control group. Animals were treated for ten minutes with the corresponding treatment every day on the right side of the mandibular condyle for four weeks. The results showed that there is a statistically significant increase (60%) in the FL in the treated condyles by the laser group compared to the counte control condyles. Also, LED increased both the FL and CL significantly and PL more than the negative control condyles (*P* \< 0.05). Although LED and FA significantly increased all condylar layers when compared to the untreated negative control condyles, LED alone was more effective in increasing condylar layers than the combined LED and FA treatment (*P* \< 0.05). On the other hand, LED and FA increased the CL more than the LLL and FA group (*P* \< 0.05). The findings of this study suggest that LED is better than LLL in stimulating mandibular condyles in growing rats ([Figure 3](#fig3){ref-type="fig"}) \[[@B92]\]. However, the exact mechanism by which LED or LLL stimulate mandibular growth is yet to be understood fully so that an optimum technique can be developed using photobiomodulation. Future studies are needed to test the hypothesis that LED treatment to mandibular condyle can modulate molecular mechanisms of mandibular growth, especially Runx2, VEGF, Sox9, and type-II collagen.

Photobiomodulation for stimulation of mandibular condylar growth may be close to application in the clinic because clinical trials using LED in patients undergoing orthodontic treatment have identified enhanced tooth movement and minimal side effects, such as root resorption.

3.4. Gene Therapy {#sec3.4}
-----------------

Gene therapy involves either physical or chemical transfer of genetic material in the host cell, \[[@B84]\]. Gene therapy involves using plasmid DNA alone (naked DNA) \[[@B94], [@B95]\] or associated with gene carriers or vectors such as nonviral vectors (liposomes or a polymer matrix) \[[@B96]\]. Liposomes have proven sufficient for gene transfer into chondrocytes, and they have several advantages over adenovirus vectors including ease of preparation, lack of limitations on the size of the DNA, and minimum immunological reaction \[[@B97]\]. However, *in vivo* or clinical application is yet to be proven. Viral vectors carrying vascular endothelial growth factor (rAAV-VEGF) have been shown to stimulate mandibular growth *in vivo* in rats \[[@B98]\]. Yet, more research is needed to optimize the technique and detailed toxicity evaluation of viral and nonviral vectors (both local and systemic), and testing optimized techniques in higher animals before clinical trials can be conducted. The hypothesis underlying local injection of vector-loaded VEGF into mandibular condyles is that this VEGF can modulate mandibular growth through added VEGF effect that has been shown to be correlated to mandibular growth stimulation \[[@B29], [@B30]\]. VEGF may stimulate mandibular growth through two mechanisms: (1) through stimulation of endochondral bone growth and (2) through recruitment of new replicating mesenchymal stem cells which is correlated to mandibular growth \[[@B34], [@B35]\]. It seems that the road towards clinical application of gene therapy to enhance mandibular condylar growth is long compared to other modalities like LIPUS or LED. Many questions remain to be answered regarding the safety, optimization, and mechanism underlying gene therapy, which is also more invasive and currently less accepted than LIPUS or LED.

4. Syndromic Mandibular Hypoplasia and Treatment Possibilities {#sec4}
==============================================================

Syndromic mandibular hypoplasia, as in hemifacial microsomia (HFM), is distinct from symmetrical mandibular hypoplasia. HFM is a congenital anomaly that is presented by asymmetric facial structures in which the mandible and overlying structures fail to develop normally. HFM is also known as otomandibular dysostosis, \[[@B99]\] first and second branchial arch syndrome, \[[@B100], [@B101]\] oculo-auriculovertebral dysplasia, \[[@B102]\] Goldenhar syndrome, \[[@B103], [@B104]\] lateral facial dysplasia; \[[@B105]\] and craniofacial microsomia \[[@B106], [@B107]\]. The prevalence of HFM has been previously reported as 1 in 3000 or 1 in 5600 births \[[@B108]--[@B111]\]. Males are more affected than females \[[@B112]\], and it has been reported that the right side is affected more than the left side (3 : 2 ratio) \[[@B113]\]. At present, the underlying cause of HFM remains unknown. It has been hypothesized that HFM results from a developmental abnormality related to hemorrhage and rupture of the stapedial artery (a small blood vessel near the ear), as supported by mouse studies \[[@B112]--[@B114]\]. It is to be noted that small animal models of HFM cannot be extrapolated to humans, as there is no published reports that indicate that hypothesized etiology of human HFM is similar to those in lower animal models. Pruzansky classification is the most known HFM classification used by clinicians and researchers \[[@B115]--[@B117]\]. Treatment of HFM depends on each case severity and patient\'s age. Treatment of HFM may include orthodontic hybrid functional appliances in less severe cases and/or surgical intervention utilizing orthognathic surgery or distraction osteogenesis \[[@B118]\]. Since the etiology of HFM is not fully understood, the use of the new proposed techniques may not be fully applicable to syndromic cases like HFM.

5. Current Challenges in Available Techniques Used to Enhance Mandibular Growth {#sec5}
===============================================================================

As noted above, although LIPUS, LED, GH, or gene therapy may be future techniques that may be used one day for mandibular stimulation in patients with underdeveloped mandibles, the following challenges are foreseen for these techniques. While optimized LIPUS treatment is hypothesized to be dose (treatment-time) dependent, it is a challenge to use LIPUS daily for more than 20 minutes per day to mandibular condyles, especially in growing children. From the preliminary study that showed a proof of principle that local rGH injection can enhance mandibular growth, possible increase in rGH dose might bring a risk of systemic unwanted effect(s). While LED treatment to growing mandibles show promising effect, the underlying mechanisms that are involved in LED-mediated mandibular growth stimulation are not known; hence, possible optimized technique of LED application is not known or cannot be hypothesized. Finally, it seems to be very early for proposing genetherapy for human mandibular growth due to the following challenges. It is not known whether locally injected vector-loaded genes have possible systemic effect or not. Although nonviral vectors have been investigated for possible future use in humans, it is not known the possible side effects of these nonviral vectors. It is also not known the optimum dose of each vector or vector-loaded gene concentration that can enhance mandibular growth without inducing unnecessary overgrowth of the mandibles or inducing neoplastic growth. With these challenges, future research may be directed towards uncovering these mechanisms and studying possible side effects as well as optimized techniques in mandibular growth stimulation.

Although shown to be a clinically acceptable treatment modality, bite-jumping appliances (functional appliances (Fas)) alone may not be fully effective in stimulating mandibular growth to the level that they can substitute surgical repositioning of the mandible in severe mandibular deficiency cases. LIPUS can stimulate mandibular growth in growing animals and in humans; however, an optimized technique to shorten treatment time requires further investigations in lower and higher animals before any clinical trials may be proposed. An optimized technique that utilizes local rGH administration with or without LIPUS is worth investigation to stimulate mandibular growth with minimum potential side effects. Gene therapy as well as LLL or LED seems to be promising approaches in stimulating mandibular growth. However, detailed toxicity investigations of these techniques are required before potential clinical trials can be performed.
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![A hemifacial microsomia patient treated with 20 minutes LIPUS per day for a year with a hybrid functional appliance. (a) Before and (b) after treatment.](BMRI2013-789679.001){#fig1}

![Effect of LIPUS and growth hormone on mandibular head length changes. (a) Measurement of mandibular head. (Straight line was drawn in between the two points that are anatomically situated in the lowest position in 2D reconstructed images. Length of mandibular head was measured by drawing a perpendicular line from the highest point of the condylar process towards the former line.) (b) Effect of treatment on the length of the mandibular head (LMH). After measurement length of the left mandibular head was divided by length of the right mandibular head. Ratio was analyzed among four different groups mentioned before. \**P* \< 0.05, compared to control.](BMRI2013-789679.002){#fig2}

![Surface area of mandibular condylar layers. (a) Fibrous, (b) proliferative, (c) hypertrophic, and (d) cartilaginous layers in rats treated by LED, laser with or without functional appliance (FA). It can be seen that LED increases surface areas in (a), (b), and (d) compared to control and almost similar to control in (c).](BMRI2013-789679.003){#fig3}
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